(Q38105532)

28 August 2017

title

Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? (English)

1 reference

28 August 2017

1 reference

1

Sai-Hong Ignatius Ou

0 references

language of work or name

English

0 references

publication date

9 May 2013

1 reference

Journal of Clinical Pathology

28 August 2017

published in

1 reference

28 August 2017

volume

66

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

839-846

1 reference

Lung cancer in never smokers--a different disease

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

RET, ROS1 and ALK fusions in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

EGFR exon 20 insertion mutation in Japanese lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

KIF5B-RET fusions in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

The introduction of systematic genomic testing for patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

KRAS mutation: should we test for it, and does it matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

The transcriptional landscape and mutational profile of lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Targeting RET Receptor Tyrosine Kinase Activation in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

FGFR1 amplification in squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2012-201296

10.1136/JCLINPATH-2012-201296

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference